OM Pharma’s Post

A new research reveals that unlike the common-cold-causing coronaviruses, SARS-CoV-2 can break down into tiny particles that overstimulate the immune system causing severe or persistent disease. #worldhealth #publichealth #globalhealth #coronavirus #covid19 #sarscov2 #longcovid #antiaging #regenerativemedicine #medicine #clinicalresearch #health https://lnkd.in/gE25n5N2

Being well into flu season, Roche Diagnostics Australia spoke with Clinical Microbiologist Professor @Paul Griffin about this year's season and what to expect. Typically, flu season begins at the beginning of April and reaches right through to the end of winter. In the video, Prof. Griffin gives us advice on common respiratory virus', common misconceptions and how medications and testing can be accessed for relevant patients. As often is the case, immunisation is better than cure. During flu season, reliable diagnostic solutions can help differentiate between the SARS-CoV-2 and influenza A/B viruses so that healthcare providers can make informed decisions on which treatments are appropriate, help improve patient outcomes, and return to a normal life. View the video of Prof. Paul Griffin below: Reference 1: https://lnkd.in/gK3x68Wp (Last accessed 11/3/24)

Did you know that 44% of infections after treatment with #bispecific antibody therapy are in the lower respiratory tract? Read our latest article to learn more about the incidence and characteristics of infections associated with the use of bsAbs! 👉 https://loom.ly/o9B9UtQ #mmsm #myeloma #MultipleMyeloma

📊 Check out our latest report highlighting breakthrough innovations to treat infectious and chronic respiratory diseases! 🔬 Through writing the editorial and summarising the top 6 breakthroughs, some key challenges stood out: 🌍 With a globally aging population and persistent air pollution, diagnoses of chronic respiratory diseases such as COPD are expected to continue rising in the coming decades. 🫁 Nearly 45% of all deaths in the 'developed' world are attributed to some type of chronic fibroproliferative disease. As such, there is a significant unmet need for the development of more effective treatments for fibrosis of the lungs. 😷 Following the COVID-19 pandemic, researchers are also prioritising preventing infections from existing and emerging infectious respiratory diseases. Read more on the landing page and report here 👇

🔬 𝐓𝐡𝐞 𝐀𝐁𝐂𝐬 𝐨𝐟 𝐘𝐨𝐮𝐫 𝐂𝐁𝐂: 𝐖𝐡𝐚𝐭 𝐘𝐨𝐮𝐫 𝐁𝐥𝐨𝐨𝐝 𝐓𝐞𝐬𝐭 𝐂𝐚𝐧 𝐓𝐞𝐥𝐥 𝐘𝐨𝐮 Curious about what a Complete Blood Count (#CBC) can reveal? The essential CBC test offers valuable insights into your overall #health, including indications of infections, anemia, and other medical conditions. Discover the importance of each component of your CBC and what it means for your health. Sterling Accuris Diagnostics provides a comprehensive guide to understanding your blood test results. 🔗 Read more: https://lnkd.in/gPsc-JCr . . . #CBCTest #CompleteBloodCount #BloodTest #Healthcare #Diagnostics #HealthTips #HealthAwareness 🩺🔍🧬 #SterlingAccurisDiagnostics #SterlingAccurisPathology #SterlingAccuris #PathologyLabThatCares

News from Gilead Sciences, Inc.! 🌟 New real-world data presented at the 31st Conference on Retroviruses and Opportunistic Infections (CROI) further support the use of Veklury® (remdesivir) for individuals hospitalized with COVID-19. Studies show Veklury's association with reduced long-COVID symptoms, decreased mortality in immunocompromised patients during the Omicron period, and improved outcomes when used in combination with dexamethasone. These findings underscore Veklury's efficacy and safety profile, reinforcing its role as the antiviral standard of care for COVID-19 hospitalizations. Join the discussion on how Veklury continues to make a positive impact in the fight against COVID-19! https://lnkd.in/eXtnsjRb 📰 Make sure you follow Practical Patient Care to receive the latest Healthcare news daily and to subscribe to our weekly newsletter #practicalpatientcare #GileadSciences #Veklury #COVID19Treatment #RealWorldData #CROI2024 🦠💊🔬

We’re thrilled to announce that the #KariusTest has been granted designation as a Breakthrough Device from the FDA for use in the diagnosis and management of immunocompromised patients with suspected lung infections, including lower respiratory infection and pneumonia. “The Karius Test is commercially available nationwide as a laboratory developed test. We are seeking FDA marketing authorization of the Karius Test for lung infections in immunocompromised patients because improved diagnostic tests are urgently needed for these patients,” said Brad Perkins, our Chief Medical Officer. As noted in the American Thoracic Society Workshop Report for Immunocompromised Host Pneumonia: Definitions and Diagnostic Criteria, lung infections have high morbidity and mortality in immunocompromised patients, which is why advances in technologies like metagenomic sequencing used for the Karius Test are vital in improving the diagnosis and treatment of these patients.” New data on the Karius Test and cost-effectiveness in pneumonia will be presented at #ATS2024. https://hubs.li/Q02xnTnm0 #FDA #pneumonia #infectiousdiseases #metagenomic #breakthroughdevice

Our article on infectious diarrhea: treatments and vaccine strategies.

Worldhealth.net #Antibodies from long Covid patients trigger symptoms in mice, pointing to the possibility that the immune system's self-attack could be driving the condition. Two recent studies suggest that this #autoimmune response might be the key factor behind the chronic symptoms seen in long Covid patients. #worldhealth #antiaging #regenerativemedicine #covid19 #clinicalresearch #health #wellness https://lnkd.in/gqWTGE2w

Factful New Insight/Clinical perspective on PASC/ Long Covid! #involvement of wide range of tissues and coexisting conditions a causal factor for PASC/Long covid#